“…Since most of the papers focus on HIV prevention, the value dimension mainly focuses on the number of infections averted and the number of new infections (i.e. Alistar et al , 2014; Earnshaw et al , 2007; Juusola and Brandeau, 2016; Kassa, 2018; Kessler et al , 2013; Kok et al , 2015; Lasry et al , 2011, 2007; Malvankar and Zaric, 2011; McCoy and Johnson, 2014; Richter et al , 1999; Yaylali et al , 2016; Zaric and Brandeau, 2001a, 2007). This dimension also includes the quality-adjusted-life-years (QALYs) (Alistar et al , 2014; Deo et al , 2015; Juusola and Brandeau, 2016; Zaric and Brandeau, 2001a), the number of HIV-positive people receiving treatment (Barrow et al , 2020; Jónasson et al , 2017), the number of patients receiving their test results (Deo and Sohoni, 2015; Jónasson et al , 2017), the number of persons served (de Vries et al , 2020; Núñez Ares et al , 2016; Yaylali et al , 2016), patient adherence (McCoy and Johnson, 2014), the number of patients achieving viral suppression (Barrow et al , 2020) and the accessibility of HIV services (de Vries et al , 2020; Núñez Ares et al , 2016).…”